WHO ICTRP trial
Escitalopram efficacy and tolerability in treatment resistant depression. an…
ACTRN12613000256774 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12613000256774 |
|---|---|
| Public title | Escitalopram efficacy and tolerability in treatment resistant depression. an open study. |
| Scientific title | The objective of this European multicentre study was to evaluate escitalopram efficacy and tolerability in a population which has been shown to have Treatment Resistant Depression (TRD) in a prospective open treatment phase with venlafaxine over a 6 week period at an adequate dose after non response… |
| Primary sponsor | Lundbeck |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | Belgium;Austria;Italy;Israel;France;Greece |
| Conditions | Major Depression; Major Depression;Mental Health - Depression |
| Interventions | Patients meeting the entry criteria and for whom the investigator considered switching to venlafaxine, were included in a 6 week prospective treatment with venlafaxine (AD2) prescribed continuously at its optimal dose. Initial venlafaxine… |
| Registration date | May 3, 2013 |
| Target size | 417 |
| Secondary IDs | nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: